Menu Search
Equities

Bioretec Oy

0TN:FRA

Bioretec Oy

Actions
  • Price (EUR)1.91
  • Today's Change0.000 / 0.00%
  • Shares traded10.00
  • 1 Year change-13.57%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioretec Oy is a Finland-based medical device manufacturer company focusing on the development of strong, safe and reliable bioresorbable implants for pediatric and adult orthopedics. The Company operates as a developer, manufacturer and commercializer of innovative bioresorbable orthopedic implants and implant materials used for the treatment of bone and soft tissue injuries. Bioretec Oy’s existing Activa product portfolio consists of bioabsorbable biopolymer products that are alreadyavailable in the market for applications in pediatrics, trauma surgery as well as sports surgery. Bioretec Oy has one Germany-based subsidiary, BRI.Tech GmbH. The Company’s products are used all over the world.

  • Revenue in EUR (TTM)4.08m
  • Net income in EUR-3.53m
  • Incorporated1998
  • Employees43.00
  • Location
    Bioretec OyYrittajankulma 5TAMPERE 33710FinlandFIN
  • Phone+358 207789500
  • Fax+358 33170225
  • Websitehttps://bioretec.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.